Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R1VU
|
|||
| Former ID |
DCL000194
|
|||
| Drug Name |
Perifosine
|
|||
| Synonyms |
D 21266; NKA17; D-21266; KRX-0401; KRX-0401, NSC 639966; Octadecyl-(1,1-dimethyl-4-piperidylio)phosphate; Piperidinium, 4-[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt; Piperidinium, 4-((hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethyl-, inner salt; (1,1-dimethylpiperidin-1-ium-4-yl) octadecyl phosphate; 4-((Hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethylpiperidinium inner salt
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
AEterna Zentaris
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H52NO4P
|
|||
| Canonical SMILES |
CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C
|
|||
| InChI |
1S/C25H52NO4P/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-24-29-31(27,28)30-25-20-22-26(2,3)23-21-25/h25H,4-24H2,1-3H3
|
|||
| InChIKey |
SZFPYBIJACMNJV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 157716-52-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
499931, 10249827, 12014848, 14760465, 46225126, 50522741, 53788324, 57346714, 85246193, 93310442, 99437196, 103470071, 103910923, 104418415, 109693544, 118049497, 118844937, 123051101, 124756952, 124898782, 125163758, 125342051, 126635176, 126666969, 126730749, 127342249, 127342250, 134338862, 135105241, 135727424, 136380272, 137241823, 138570989, 139786486, 143493383, 144206916, 152211795, 152234886, 152258856, 152344202, 160645447, 160821709, 162011855, 162190947, 163091653, 163686461, 164041887, 164160505, 164232283, 164825248
|
|||
| ChEBI ID |
CHEBI:67272
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7424). | |||
| REF 2 | ClinicalTrials.gov (NCT00019656) Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Company report (Aezsinc) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.